ScholarWorks@Korea University College of Medicine: Park, Yong

Detailed Information

Park, Yong (박용)

Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Multiple myeloma:11||Prognosis:8||prognosis:8||diffuse large Bcell lymphoma:5||autologous stem cell transplantation:5||multiple myeloma:5||Survival:4||Diffuse large B cell lymphoma:4||Diffuse large Bcell lymphoma:4||Acute myeloid leukemia:4||Chemotherapy:3||Rituximab:3||Melphalan:3||Treatment outcome:3||Stem cell transplantation:3||Lenalidomide:2||plasma cells:2||CXCR2:2||exosome:2||Bortezomib:2||Autologous:2||progressionfree survival:2||Tyrosine kinase inhibitors:2||Mantle cell lymphoma:2||Elderly:2||Creactive protein:2||Febrile neutropenia:2||Cytogenetics:2||Neutropenia:2||central nervous system:2||Autologous stem cell transplantation:2||Lymphoma:2||Korea:2||azacitidine:2||liquid biopsy:2||Albumin:2||IL8:2||decitabine:2||Toxicity:2||Peripheral Tcell lymphoma:2||Thalidomide:2||Transplantation:2||Treatment:2||Concomitant chemoradiation:1||Consensus report:1||Consolidation chemotherapy:1||Corebinding factor:1||Coronavirus:1||Cyclophosphamide:1||D816 mutation:1||DPP4/CD26:1||Deauville scores:1||Defibrotide:1||Depression:1||Diagnosis:1||Docetaxel:1||Dose intensity:1||Drug resistance:1||ERCC1:1||Eculizumab:1||Effectiveness:1||Elderly multiple myeloma:1||Enzymelinked immunosorbent assay:1||EpsteinBarr virus:1||Etoposide:1||Extranodal NK/T cell lymphoma:1||Extranodal natural killer/T cell lymphoma:1||FDGPET:1||Female:1||Fludarabine:1||Frailty:1||GCSF:1||GCC2:1||GROA:1||Gastric MALT lymphoma:1||Genetics:1||Germinal center B cell:1||Granulocyte colonystimulating factor:1||Granulysin:1||Guidelines:1||HLAC*08:1||Hematologic malignancy:1||Hematopoietic stem cell mobilization:1||Hematopoietic stem cell transplantation:1||Highdose cytarabine:1||Human herpesvirus 8:1||Human immunodeficiency virus:1||HyperCVAD:1||Idiopathic aplastic anemia:1||Immature platelet fraction:1||Immune thrombocytopenia:1||Immunohistochemistry:1||Immunophenotype:1||Induced pluripotent stem cells:1||Inflammation:1||Intensive chemotherapy:1||International Prognostic Index:1||International prognostic index:1||Intravenous busulfan:1||Korean:1||Korean Society of Hematology Lymphoma Working Party:1||Korean aplastic anemia trials:1||Lenalidomide and dexamethasone:1||Lenalidomide plus dexamethasone:1||Leukemic stem cells:1||Limited stage:1||LongTerm Outcome:1||Lowdose dexamethasone:1||Lymphoblastic lymphoma:1||Lymphoid malignancies:1||Maintenance:1||Malignancy:1||Marginal zone B cell lymphoma:1||Marginal zone lymphoma:1||Mesenchymal Stem Cells:1||Metabolic syndrome:1||Modified:1||Monocytosis:1||Morphologyaided laser microdissection:1||Myelofibrosis:1||Myeloma:1||Nasopharyngeal carcinoma:1||National Health Insurance:1||Nationwide analysis:1||Neoplasm invasiveness:1||Neutrophillymphocyte ratio:1||NonHodgkin's lymphoma:1||Nongerminal center B cell:1||Obesity:1||PET:1||PLR:1||POEMS Syndrome:1||PVR:1||Paroxysmal nocturnal hemoglobinuria:1||Partial response:1||Pegfilgrastim:1||Phase II:1||Philadelphia chromosome:1||Placenta:1||Platelet count:1||Platelet function analyzer:1||Ponatinibresistant CML:1||Population study:1||Prednisone:1||Primary adrenal lymphoma:1||Primary effusion lymphoma:1||Prognostic factor:1||Prophylaxis:1||RCHOP:1||RCVP:1||RASSF1A:1||RUNX1/RUNX1T1:1||Radiotherapy:1||Realworld:1||Realworld evidence:1||Red Blood Cell Transfusion:1||Refractory:1||Relapse:1||Relapsed and refractory:1||Relapsed and refractory multiple myeloma:1||Relapsed lymphoma:1||Retrospective analysis:1||Ruxolitinib:1||Salvage chemotherapy:1||Screening test:1||Simplified geriatric assessment:1||Single cell analysis:1||Squamous cell carcinoma of the head and neck:1||Stem cell:1||Stem cell dose:1||Stem cell source:1||Stemness:1||Stomach neoplasm:1||Surgery:1||Tcell:1||Tcell lymphoma:1||TIGIT:1||Targeted sequencing:1||Thrombocytopenia:1||Thrombomodulin:1||Transfusion:1||Treatment pattern:1||Treatmentrelated mortality:1||Tumorigenesis:1||Type 2 diabetes mellitus:1||Venoocclusive disease:1||Vorinostat:1||Young adult:1||acquired:1||acute promyelocytic leukemia:1||alltrans retinoic acid:1||antifungal prophylaxis:1||antiviral therapy:1||atypical lymphoid hyperplasia:1||autoantibodies:1||biomarker:1||biomarkers:1||biosimilar:1||bone marrow involvement:1||busulfan:1||cMyc:1||cancer:1||cereblon:1||chemotherapy:1||comparison:1||conditioning regimen:1||cytomegalovirus:1||cytomegalovirus lymphadenitis:1||deep learning:1||discontinuation:1||early detection:1||early mortality:1||essential thrombocythemia:1||etoposide:1||exosomes:1||factor 8 deficiency:1||febrile neutropenia:1||galectin9 (Gal9):1||haemorrhage:1||haemostasis:1||hepatitis B virus:1||high risk:1||hypomethylating agent:1||immunoglobulin gene rearrangement:1||immunomodulatory therapy:1||immunosuppressive agents:1||incidence:1||induced pluripotent stem cells:1||international prognostic index:1||invasive fungal infection:1||lactate dehydrogenase:1||lung cancer diagnosis:1||lymphoblastic leukemia:1||lymphoma:1||mTOR:1||mTOR activator:1||mobilization:1||myelodysplastic syndrome:1||myelodysplastic syndromes:1||myelofibrosis:1||myeloproliferative neoplasms:1||neutropenia:1||new allele:1||nomograms:1||nonHodgkin:1||nonhodgkin lymphoma:1||nonsmall cell lung cancer:1||overall survival:1||pegylated granulocytecolony stimulating agent:1||phase IV clinical trial:1||pluripotency signaling pathway:1||posaconazole:1||primary breast lymphoma:1||programmed deathligand 1 (PDL1):1||propensity score:1||prophylaxis:1||pulmonary lymphomatoid granulomatosis:1||pulmonary tuberculosis:1||reprogramming efficiency:1||risk stratification:1||rituximab:1||ruxolitinib:1||stem cell transplantation:1||surfaceenhanced Raman spectroscopy (SERS):1||surgical procedures:1||survival:1||tenofovir disoproxil fumarate:1||thromboembolism:1||transplantation:1||transplantation conditioning:1||변연부B세포림프종:1||위말트종:1||228:1||항암치료:1||Acute myelogenous leukemia:1||Adherence:1||Adjuvant chemotherapy:1||Adult:1||Aging:1||Alemtuzumab:1||Allogeneic hematopoietic stem cell transplantation:1||Anagrelide:1||Anemia:1||Ann Arbor stage:1||Anthracyclines:1||Asia:1||Atypical Hemolytic Uremic Syndrome:1||Atypical hemolytic uremic syndrome:1||Autologous Stem Cell Transplantation:1||Autologous hematopoietic stem cell transplantation:1||Autologous transplantation:1||BCRABL:1||Bendamustine:1||Bicarbonate:1||Bleeding:1||Body cavitybased lymphoma:1||Bone Marrow:1||Bone marrow involvement:1||Bone morphogenetic protein 2:1||Burkitt lymphoma:1||Busulfan:1||CD155:1||CMV:1||CT:1||CVAD protocol:1||CXCR2 human pluripotent stem cells:1||CXCR2 ligands:1||Carfilzomib:1||Chromosomal abnormalities:1||Chronic myelogenous leukaemia:1||Chronic myeloid leukemia:1||Chronic myelomonocytic leukemia:1||Cisplatin:1||Clinical outcomes:1||Clostridium difficile:1||Complication:1||

STATISTICS: Total View :12,811,681; Today View :8,467

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE